odanacatib (MK-0822) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00691899 / 2008-002120-29: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Withdrawn
3
0
US
odanacatib, MK0822, placebo (unspecified)
Merck Sharp & Dohme LLC
Prostate Cancer
09/08
09/08
NCT00692458 / 2008-002119-42: A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Withdrawn
3
0
US
Comparator: odanacatib, Comparator: placebo
Merck Sharp & Dohme LLC
Breast Cancer
09/08
09/08
NCT00729183 / 2008-004504-31: Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Completed
3
214
NA
Odanacatib, MK-0822, Placebo, Vitamin D3, Calcium supplement, calcium carbonate, calcium citrate
Merck Sharp & Dohme LLC
Osteoporosis
03/10
03/11
NCT00529373 / 2011-005514-10: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Terminated
3
16071
NA
Odanacatib, MK-0822, Placebo for Odanacatib, Vitamin D3, Calcium carbonate, Calcium supplements
Merck Sharp & Dohme LLC
Postmenopausal Osteoporosis
11/12
02/17
MK-0822-053, NCT01120600: A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis

Completed
3
294
NA
Odanacatib, MK-0822, Placebo for Odanacatib, Vitamin D3, Calcium carbonate
Merck Sharp & Dohme LLC
Osteoporosis
07/13
07/13
2010-019454-41: A Phase III Study to Assess the Safety and Efficacy of Odanacatib (MK 0822) in Men with Osteoporosis Treated with Vitamin D and Calcium

Completed
3
360
Europe, RoW
MK-0822; Chemical name: N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4’-(methylsulfo, MK-0822, Tablet
Merck Sharp & Dohm Corp., Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme B.V., MERCK & CO., INC., , Merck & Co., Inc.
osteoporosis, osteoporosis, Body processes [G] - Bones and nerves physological processes [G11]
 
 
NCT01803607: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Terminated
3
135
NA
odanacatib, MK-0822, placebo to odanacatib
Merck Sharp & Dohme LLC
Osteoporosis
11/14
11/14
2014-002587-33: Extension to the Odanacatib Fracture Trial (PN018)

Ongoing
3
5000
Europe
Odanacatib, MK-0822, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
osteoporosis, endocrinology, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
NCT01552122: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Withdrawn
3
0
US
Odanacatib, MK-0822, Alendronate, Alendronate Sodium, Fosamax, Placebo (odanacatib), Cholecalciferol (Vitamin D3), Calcium carbonate, Placebo (alendronate)
Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal Osteoporosis
02/15
02/15
2008-004578-42: An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

 
3
400
Europe
MK-0822; Chemical name N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4\'-(methylsulfo, cholecalciferol (Vitamin D3), MK-0822
Merck & Co. Inc., Merck & Co., Inc.
Postmenopausal Osteoporosis
 
 
2008-005874-11: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated with Vitamin D and Calcium

Ongoing
3
55
Europe
Laboratoires Merck Sharp & Dhome-Chibret
This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) for osteoporosis as a starting point for identification of molecular biomarkers in circulating blood for patient identification and sarcopenia progression. Patients recruited in Protocol 018 are women 65 years of age or older with osteoporosis and either 0 or 1 prior vertebral fracture.
 
 
2009-011920-69: A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Ongoing
3
20
Europe
Merck & Co., Inc.
postmenopausal osteoporosis
 
 
2013-001526-26: An Observational follow-up study to Protocol 018

 
3
540
Europe, RoW
MK-0822, MK-0822,
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Osteoporosis
 
04/15
2007-002693-66: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Completed
3
16300
Europe, RoW
MK-0822; Chemical name: N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4’-(methylsulfo, MK-0822, Tablet, VITAMINA D3 500000UI/G POLV1KG
MERCK SHARP & DOHME CORP., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A., Laboratoires Merck Sharp & Dohme - Chibret, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck & Co., Inc, MERCK SHARP DOHME ITALIA S.P.A., Merck & Co., Inc., MERCK SHARP & DOHME CORP., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck and Co.,, , Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A., Merck & Co.,Inc., MERCK SHARP & DOHME CORP., a subsidiary of Merck & Co., Inc, Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.
Postmenopausal Osteoporosis, Postmenopausal Osteoporosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2005-001511-22: A Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) vs placebo in the Treatment of Women With Osteoporosis

Completed
2/3
375
Europe, RoW
L-001037536, MK-0822, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp.,
Postmenopausal Osteoporosis
 
 

Download Options